- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.07. | Journey Medical Corp - 8-K, Current Report | 3 | SEC Filings | ||
| 14.07. | Journey Medical's rosacea treatment reaches 65% commercial coverage | 2 | Investing.com | ||
| 14.07. | Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi | 2 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical to join Russell 2000 and 3000 indexes | 3 | Investing.com | ||
| 24.06. | Journey Medical Corporation: Journey Medical to Join Russell 2000 and Russell 3000 Indexes | 1 | GlobeNewswire (USA) | ||
| 24.06. | Journey Medical Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 20.06. | Journey Medicals Rosacea-Medikament zeigt Wirksamkeit unabhängig vom Gewicht | 1 | Investing.com Deutsch | ||
| 09.06. | Journey Medical Corporation Announces Emrosi Featured on "The Balancing Act" Airing on Lifetime TV | 2 | GlobeNewswire (USA) | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 15.05. | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 15.05. | Journey Medical GAAP EPS of -$0.18 beats by $0.06, revenue of $13.1M beats by $1.05M | 2 | Seeking Alpha | ||
| 15.05. | Journey Medical outlines Emrosi launch momentum and targets expanded payer access in 2025 | 2 | Seeking Alpha | ||
| 14.05. | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 106 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 07.05. | Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025 | 2 | GlobeNewswire (USA) | ||
| 30.04. | Why Journey Medical Corporation (DERM) is Surging in 2025 | 1 | Insider Monkey | ||
| 03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 119 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
| 26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
| 26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 660 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,105 | -0,09 % | Dividendenbekanntmachungen (25.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,1276 EUR AVI GLOBAL TRUST PLC GB00BLH3CY60 0,015 GBP EUR BANK OF NEW YORK MELLON... ► Artikel lesen | |
| GILEAD SCIENCES | 98,96 | 0,00 % | Gilead Sciences, Inc.: Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention | - If Approved, Lenacapavir Would Be the First and Only Twice-Yearly HIV PrEP Option in the European Union - - Positive Opinion Also Received for EMA's EU-M4all Procedure, Designed to Facilitate... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 399,30 | -0,15 % | Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis | ||
| EYEPOINT PHARMACEUTICALS | 8,586 | -3,74 % | EyePoint Pharmaceuticals, Inc.: EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ROCKET LAB | 40,200 | -0,50 % | Rocket Lab Trimmed From Cathie Wood's Space ETF: Strategy Or Signal? | ||
| ASTRIA THERAPEUTICS | 5,600 | -1,75 % | Astria Therapeutics, Inc.: Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress | -- Q3M Arm Demonstrated 95% Mean Monthly Attack-Rate Reduction -- -- Q6M Arm Demonstrated 86% Mean Monthly Attack-Rate Reduction - -- Well-Tolerated with a Favorable Safety Profile -- --... ► Artikel lesen | |
| OPKO HEALTH | 1,168 | +0,50 % | OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) | ||
| LIGAND PHARMACEUTICALS | 113,00 | -2,59 % | Ligand Pharmaceuticals: Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 | ||
| JAZZ PHARMACEUTICALS | 100,40 | -0,30 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025 | DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after... ► Artikel lesen | |
| ROYALTY PHARMA | 31,120 | -0,38 % | Citi raises Royalty Pharma stock price target to $42 on CF and Tremfya growth | ||
| CATALYST PHARMACEUTICALS | 17,925 | -0,25 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| TG THERAPEUTICS | 31,620 | +0,67 % | TG Therapeutics, Inc.: TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance | First quarter 2025 BRIUMVI U.S. net revenue of $119.7 million Raises full year 2025 global net revenue target to approximately $575 million and raises full year BRIUMVI U.S. net revenue target to... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,850 | 0,00 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals... ► Artikel lesen | |
| CATALENT | 59,93 | 0,00 % | GenSight Biologics Announces Significant Milestone in New Manufacturing Partnership with Catalent | Upstream phase of LUMEVOQ manufacturing process successfully transferred
Milestone follows successful manufacture of drug product batch to be used for named early access program (AAC) and... ► Artikel lesen | |
| TALPHERA | 0,325 | -1,37 % | Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025... ► Artikel lesen |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 7,595 Euro und damit -0,98 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.